In 1844, Michele Peyrone synthesized cisplatin (cis-platinum(II)-diammine-dichloride, CDDP) without being aware of its tumor-inhibiting effect. Not until the mid-1960s, Barnett Rosenberg discovered the inhibition of cell division in the presence of cisplatin. Due to its outstanding effectiveness in treating numerous tumors, cisplatin became the prototype for a new class of antineoplastic substances. Meanwhile, it has become one of the most frequently used cytotoxic drugs in tumor therapy. However, its use is limited due to its side effects and the development of resistance which has led to the search for new platinum complexes.
Most of the platinum complexes are uncharged cis configurated square-planar platinum(II) complexes that can be described by the general formula cis-[PtA2 X2], with A2 as either two monodentate or one bidentate stable amine ligand(s) and X2as two...
KeywordsNucleotide Excision Repair Platinum Complex Post Replicative Repair Nucleotide Excision Repair System Metastatic Ovarian Tumor
- Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Kastedo M, Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31:1869–1883Google Scholar
- Dilruba S, Kalayda GV (2016) Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol Epub ahead of printGoogle Scholar